

Policy Number	SUR703.041
Policy Effective Date	06/15/2026

Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Table of Contents
Coverage
Policy Guidelines
Description
Rationale
Coding
References
Policy History

Related Policies (if applicable)
None

Disclaimer

Carefully check state regulations and/or the member contract.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. **If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.**

Coverage

Allogeneic hematopoietic cell transplantation (HCT) **may be considered medically necessary** as a treatment of chronic myeloid leukemia (CML).

Autologous HCT **is considered experimental, investigational and/or unproven** as a treatment of CML.

Policy Guidelines

None.

Description

Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of a chromosomal abnormality called the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of chromosomes 9 and 22. This cytogenetic change results in constitutive activation of the fusion gene BCR-ABL, a tyrosine kinase (TK) that stimulates unregulated cell proliferation, inhibits cell apoptosis, creates genetic instability, and upsets interactions between CML cells and the bone marrow stroma only in malignant cells. The disease accounts for about 15% of newly diagnosed cases of leukemia in adults and occurs in 1 to 2 cases per 100,000 adults. (1)

The natural history of the disease consists of an initial (indolent) chronic phase, lasting a median of 3 years, which typically transforms into an accelerated phase, followed by a “blast crisis,” which is usually the terminal event. Most patients present in chronic phase, often with nonspecific symptoms secondary to anemia and splenomegaly. A diagnosis is based on the presence of the Ph chromosome abnormality by routine cytogenetics, or by detection of abnormal BCR-ABL products by fluorescence in situ hybridization (FISH) or molecular studies, in the setting of persistent unexplained leukocytosis. Conventional dose chemotherapy regimens used for chronic phase disease can induce multiple remissions and delay the onset of blast crisis to a median of 4 to 6 years. However, successive remissions are invariably shorter and more difficult to achieve than their predecessors.

Treatment

Historically, the only curative therapy for CML in blast phase has been allogeneic hematopoietic cell transplantation (allo-HCT), which was used more widely earlier in the disease process given the lack of other therapies for chronic phase CML. Drug therapies for chronic phase CML were limited to nonspecific agents including busulfan, hydroxyurea, and interferon- α . (1)

Imatinib mesylate (Gleevec®), a selective inhibitor of the abnormal BCR-ABL tyrosine kinase protein, is considered the treatment of choice for newly diagnosed CML. While imatinib can be highly effective in suppressing CML, it is not curative and is ineffective in 20% to 30% of patients, initially or due to development of *BCR-ABL* variants that cause resistance to the drug. Even so, the overall survival (OS) of patients who present in chronic phase is greater than 95% at 2 years and 80% to 90% at 5 years. (2)

For CML, 2 other tyrosine kinase inhibitors ([TKIs]; dasatinib, nilotinib) have received marketing approval from the U.S. Food and Drug Administration (FDA) as first-line therapies or following failure or patient intolerance of imatinib. Three additional TKIs (bosutinib, ponatinib, and asciminib) have been approved for use in patients resistant or intolerant to prior therapy.

For patients on imatinib who have disease progression, the therapeutic options include increasing the imatinib dose, changing to another TKI, or allo-HCT. Detection of *BCR-ABL* variants may be important in determining an alternative TKI; the presence of the *T315I* variant is associated with resistance to all TKIs and should indicate the need for allo-HCT or experimental therapy. Tyrosine kinase inhibitors have been associated with long-term

remissions; however, if disease progression occurs on TKI therapy, allo-HCT is generally indicated and offers the potential for cure.

Hematopoietic Cell Transplantation

Hematopoietic cell transplantation is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function in cancer patients who receive bone marrow-toxic doses of cytotoxic drugs with or without whole body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allo-HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. In allo-HCT, immunologic compatibility between donor and patient is a critical factor for achieving a successful outcome. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. Human leukocyte antigen refers to the gene complex expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. An acceptable donor will match the patient at all or most of the HLA loci.

Conditioning for Hematopoietic Cell Transplantation

Conventional Conditioning

The conventional (“classical”) practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to cause bone marrow ablation in the recipient. The beneficial treatment effect of this procedure is due to a combination of the initial eradication of malignant cells and subsequent graft-versus-malignancy effect mediated by non-self-immunologic effector cells. While the slower graft-versus-malignancy effect is considered the potentially curative component, it may be overwhelmed by existing disease in the absence of pretransplant conditioning. Intense conditioning regimens are limited to patients who are sufficiently medically fit to tolerate substantial adverse effects. These include opportunistic infections secondary to loss of endogenous bone marrow function and organ damage or failure caused by cytotoxic drugs. Subsequent to graft infusion in allo-HCT, immunosuppressant drugs are required to minimize graft rejection and graft-versus-host disease, which increases susceptibility to opportunistic infections.

The success of autologous HCT is predicated on the potential of cytotoxic chemotherapy, with or without radiotherapy, to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of the bone marrow with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. Therefore, autologous HCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HCT are also susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment but not graft-versus-host disease.

Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation

Some individuals for whom a conventional myeloablative allotransplant could be curative may be considered for RIC allo-HCT. They include those individuals whose age (typically >60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status score) preclude use of a standard myeloablative conditioning regimen.

Reduced-intensity conditioning refers to the pretransplant use of lower doses of cytotoxic drugs or less intense regimens of radiotherapy than are used in traditional full-dose myeloablative conditioning treatments. Although the clinical definition of RIC is variable, with numerous versions employed, all regimens seek to balance the competing effects of relapse due to residual disease and non-relapse mortality. The goal of RIC is to reduce disease burden and to minimize associated treatment-related morbidity and non-relapse mortality in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. Reduced-intensity conditioning regimens range from nearly total myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism. In this policy, the term *reduced-intensity conditioning* will refer to all conditioning regimens intended to be nonmyeloablative.

Regulatory Status

The U.S. Food and Drug Administration (FDA) regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Rationale

While the coverage of this policy does not address myeloablative (MA) (also known as high-dose chemotherapy [HDC]) or reduced intensity conditioning (RIC) prior to hematopoietic cell transplantation (HCT), discussion of HCT outcomes may be influenced by the type of preparative conditioning completed prior to the transplantation. The following is a summary of the key literature to date.

Medical policies assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

Clinical Context and Therapy Purpose

The purpose of allo-HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with chronic myeloid leukemia (CML).

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with CML.

Interventions

The therapy being considered is allo-HCT.

Comparators

Comparators of interest include cytotoxic chemotherapy and treatment with tyrosine kinase inhibitors (TKIs).

Outcomes

The general outcomes of interest are overall survival (OS), disease-specific survival (DSS), treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to relevant outcomes.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Randomized Controlled Trials

In the pre-TKI era, allo-HCT was the standard of care for CML. Evidence in support of allo-HCT includes a 2015 RCT comparing primary HCT from a matched family donor (n=166) with best available drug treatment (n=261), which enrolled patients from 1997 to 2004. (3) There were no differences in 10-year OS between groups (0.76 for HCT patients versus 0.69 for drug treatment patients). Those with low transplant risk treated with HCT had improved survival compared with those treated with medical therapy but, after patients entered blast crisis, survival did not differ between groups.

The advent of TKI therapy has altered the treatment paradigm for CML such that most patients are treated initially with a TKI until the disease progresses. While progression may occur within months of starting a TKI, progression may be delayed for years, as shown by the results of the International Randomized Study of Interferon and STI571 (IRIS) trial (4) and other studies. (5, 6) With the addition of 3 other TKIs (nilotinib, dasatinib, bosutinib) plus the possibility of effective dose escalation with imatinib to override resistance, it is possible to maintain a typical CML patient past the upper age limit (usually 50 to 55 years) at which a myeloablative allo-HCT is considered an option. (4, 7, 8)

Nonrandomized Studies

Several nonrandomized studies have compared treatment using TKI therapy with allo-HCT in CML patients. Liu et al. (2013) evaluated outcomes for CML patients who underwent HCT after imatinib failure. (9) They retrospectively evaluated 105 patients with newly diagnosed chronic phase CML seen at a single institution from 1999 to 2011. Sixty-six patients received first-line imatinib therapy, 26 (treated before 2003) received interferon followed by imatinib, and 13 received first-line allo-HCT with curative intent. Twenty-two (21%) patients received allo-HCT overall, including 13 as first-line therapy and 9 following imatinib failure. Compared with those who received first-line allo-HCT, those who underwent HCT following imatinib failure had higher European Group for Blood and Marrow Transplantation (EBMT) risk scores (p=0.03). Among those receiving allo-HCT (n=22; median follow-up, 134 months; range, 6 to 167 months), patients with imatinib failure and disease progression had a significantly worse OS (p=0.015) compared with those receiving allo-HCT as first-line therapy. Patients receiving first-line allo-HCT had a 3-year OS rate of 91.7% (95% confidence interval [CI], 29 to 38 months); 1 patient in this group died of relapse and 1 of chronic graft-versus-host disease (GVHD).

Xu et al. (2015) retrospectively compared second-generation TKI therapy with allo-HCT in 93 patients in accelerated-phase CML. (10) The second-generation TKI therapy group included 33 subjects, most of whom had been previously treated with another TKI (31 with imatinib, 2 with nilotinib). Of 60 patients treated with allo-HCT, 10 were treated with HCT for the first time, and 50 had been previously treated with imatinib. Median OS was significantly shorter with second-generation TKI treatment (22 months) than with allo-HCT (82 months). Median progression-free survival and event-free survival (EFS) rates were similarly shorter with second-generation TKI treatment than with allo-HCT.

Zhang et al. (2016) retrospectively compared imatinib (n=292) with allo-HCT (n=141) in patients who had CML. (11) Survival rates were significantly longer in the imatinib group than in the allo-HCT group; 5-year EFS rates were 84% and 75% ($p<0.05$) and 5-year OS rates were 92% and 79%, both respectively. Findings were similar for patients with chronic phase and advanced phase disease.

Several studies have compared outcomes for CML patients treated with allo-HCT in the pre- and current TKI eras. While these studies have generally reported no worsening in treatment outcomes for allo-HCT following TKI therapy, they are limited by their underlying differences in treatment regimens from different eras. In a retrospective analysis by Shen et al. (2015), of the 106 patients who underwent allo-HCT and who either did (n=36) or did not (n=70) receive prior treatment with TKIs, no significant differences were reported in 10-year relapse-free survival (RFS) or OS rates. (12) However, TKI-treated patients had a higher incidence of 0.5-year transplant-related mortality. In another retrospective analysis comparing patients treated using allo-HCT in the pre-TKI era (1989 to 2001; n=39) with those treated in the TKI era (2002 to 2013; n=30), Chamseddine et al. (2015) reported longer 3-year OS and leukemia-free survival among patients treated in the TKI era. (13)

Case Series

A number of case series, primarily involving a single center, have reported outcomes for patients treated with allo-HCT following TKI treatment failure. In a 2015 series of 51 patients given allo-HCT, 32 of whom were treated for TKI resistance or intolerance, 8-year OS and EFS rates were 68% and 46%, respectively. (14) Another 2015 prospective series of 28 patients who underwent allo-HCT after the failure of at least 2 TKIs reported deep molecular remission in 18 subjects. (15) However, all 6 patients transplanted in blast crisis died. In a smaller series, Zhao et al. (2014) reported on outcomes for 12 patients with CML who experienced disease progression on imatinib and received dasatinib or nilotinib followed by allo-HCT at a single center. (16) After a median follow-up of 28 months (range, 12 to 37 months) after allo-HCT, 8 (66.7%) of 12 patients were alive, including 7 with complete molecular remission.

In addition to being used prior to allo-HCT, TKI therapy may be used after HCT to prevent or treat disease relapse. Egan et al. (2015) retrospectively analyzed patients at a single institution who underwent allo-HCT for CML and Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) and had detectable BCR-ABL transcripts by polymerase chain reaction (PCR), as well as ribonucleic acid (RNA) available for sequencing of the ABL kinase domain, in both the pre- and post-HCT settings to evaluate the impact of pre-HCT variants in the ABL kinase domain on post-HCT relapse. (17) Among 95 patients with CML with available PCR transcripts, 10 (10.5%) were found to have pre-HCT ABL kinase variants known to confer resistance to TKIs. Of those with CML, 88.4% underwent myeloablative chemotherapy, and 11.6% underwent nonmyeloablative chemotherapy. Twenty-nine CML patients received post-HCT TKIs: 19 (65.5%) for prophylaxis and 10 (34.5%) for treatment of refractory or relapsed disease. In 9 (64.2%) of the 14 patients with pre-HCT variants (which included both CML and Ph chromosome-positive ALL), the same variants conferring TKI resistance was also detectable after allo-HCT. Among the 14 with pre-HCT variants, 8 (57.1%) received a TKI in the post-HCT

setting, and 7 (50%) demonstrated post-HCT refractory disease or relapse. Of the 7 with relapsed disease, 6 had been given a predictably ineffective TKI within the first 100 days after allo-HCT, based on variant analysis conducted by the authors.

Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning

Techniques for allo-HCT have continued to develop, with important advancements in the use of nonmyeloablative or RIC preparative regimens. Overall, among 9 studies evaluated in a 2007 review, outcomes with RIC allogeneic transplants were similar to those with conventional allotransplants, with OS rates ranging from 35% at 2.5 years to 85% at 5 years among patients in chronic phase at transplant. (18) Among the studies assessed in this review, treatment-related mortality or non-relapse mortality ranged from 0% to 29% at 1 year. In the largest retrospective study, the EBMT (2005) evaluated 186 patients. (19) The OS rate was 54% at 3 years using a variety of RIC regimens in patients in chronic phase 1 (n=118), chronic phase 2 (n=26), acute phase (n=30), and blast crisis (n=12). Among patients transplanted in the first chronic phase, the OS rate was 69% at 3 years.

Reduced-intensity conditioning regimens have many of the same limitations as standard-intensity conditioning: relapse, GVHD, and mortality from treatment-related causes other than myelotoxicity. However, in the absence of prospective, comparative, randomized trials, only indirect comparisons can be made between the relative clinical benefits and harms associated with myeloablative and RIC regimens with allo-HCT. Comparison of study results is further compromised by heterogeneity across patients, treatments, and outcome measures. Nonetheless, clinical evidence has suggested outcomes in CML are similar between myeloablative and RIC allo-HCT. (5, 18, 19)

Section Summary: Allogeneic Hematopoietic Cell Transplantation

Allogeneic hematopoietic cell transplantation is accepted as a standard treatment in CML, although the use of targeted TKI therapy has allowed many patients who would previously have required allo-HCT to forestall or avoid transplantation altogether. Direct comparisons between myeloablative and nonmyeloablative RIC regimens are not available, but the available evidence has suggested that allo-HCT following nonmyeloablative conditioning regimens can lead to short- and medium-term survival rates that are on the order of those seen after myeloablative conditioning regimens. Although research into the optimal timing of allo-HCT in the setting of TKI therapy is limited, the available evidence has suggested that pretreatment with TKIs does not worsen outcomes after allo-HCT and may improve outcomes.

Autologous Hematopoietic Stem Cell Transplantation

Clinical Context and Therapy Purpose

The purpose of autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with CML.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with CML.

Interventions

The therapy being considered is autologous HCT.

Comparators

Comparators of interest include cytotoxic chemotherapy and treatment with TKIs.

Outcomes

The general outcomes of interest are OS, DSS, treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to relevant outcomes.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Nonrandomized Studies

A major limitation in the use of autologous HCT in patients with CML is a high probability that leukemic cells will be infused back into the patient. However, it is recognized that many CML patients still have normal marrow stem cells. Techniques used to isolate and expand this normal clone of cells have included ex vivo purging, long-term culture, and immunophenotype selection. (20) Even without such techniques, there are isolated case reports of partial cytogenetic remissions after autologous HCT, and a 1997 study suggested that patients undergoing such therapy may have improved survival compared with historical controls. (21)

In the pre-TKI era, there was active research into the use of autologous HCT for CML. McGlave et al. (1994) reported on outcomes for 200 consecutive autologous transplants using purged or unpurged marrow from 8 different transplant centers over 7 years. (22) Of the 200 patients studied, 125 were alive at a median follow-up of 42 months. Of the 142 transplanted in chronic phase, median survival had not been reached at the time of publication, while the median survival was 35.9 months for those transplanted during an accelerated phase. Other data consist of a small, single-institution case series using a variety of techniques to enrich the population of normal stem cells among the harvested cells. (21)

Additional reports of small, uncontrolled studies with a total of 182 patients (range, 15 to 41 patients) given autologous HCT for CML included patient populations that varied across the

studies. Some (2000, 2001) focused on newly diagnosed patients or those in the first year since diagnosis. (23, 24) Others (1999, 2000) have focused on patients who did not respond to or relapsed after initial treatment using interferon alfa. (25, 26) Finally, some have focused on patients transplanted in the late chronic phase (2000) (27) or after transformation to accelerated phase or blast crisis (1999). (28) Although some patients achieved complete or partial molecular remission and long-term disease-free survival, these studies do not permit conclusions free from the influence of selection bias. All auto-transplanted patients included in these reports were treated before imatinib mesylate or newer TKIs became available.

Section Summary: Autologous Hematopoietic Stem Cell Transplantation

No controlled studies have evaluated autologous HCT for treatment of CML. The available data consists of case reports and case series. In the largest series (N=200 patients), median survival was 36 months for patients transplanted during an accelerated phase and median survival data were not available for patients transplanted in chronic phase. Controlled studies are needed to permit conclusions about the impact of autologous HCT on health outcomes in patients with CML.

Summary of Evidence

For individuals who have chronic myeloid leukemia (CML) who receive allogeneic hematopoietic cell transplant (allo-HCT), the evidence includes systematic reviews, randomized controlled trials, and multiple prospective and retrospective series. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. The introduction of tyrosine kinase inhibitors (TKIs) has significantly changed the clinical use of hematopoietic cell transplantation (HCT) for CML. TKIs have replaced HCT as initial therapy for patients with chronic phase CML. However, a significant proportion of cases fail to respond to TKIs, develops a resistance to them, or cannot tolerate TKIs and proceed to allo-HCT. Also, allo-HCT represents the only potentially curative option for those patients in accelerated or blast phase CML. Currently, available evidence has suggested that TKI pretreatment does not lead to worse outcomes if HCT is needed. Myeloablative conditioning regimens before HCT are used in younger (<60 years) patients without significant comorbidities. However, for patients with more comorbidities and/or more advanced age for whom myeloablative conditioning regimens would be prohibitively high-risk, evidence has suggested that reasonable outcomes can be obtained after HCT. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have CML who receive autologous HCT, the evidence includes case series. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. In the largest series (N=200 patients), median survival was 36 months for patients transplanted during an accelerated phase; median survival data were not available for patients transplanted in chronic phase. Controlled studies are needed to permit conclusions on the impact of autologous HCT on health outcomes in patients with CML. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

American Society for Transplantation and Cellular Therapy

In 2020, the guidelines by the American Society for Transplantation and Cellular Therapy (formerly the American Society for Blood and Marrow Transplantation) addressed indications for autologous and allo-HCT for CML. (29) Recommendations are listed in Table 1.

Table 1. Recommendations on Allogeneic and Autologous HCT for CML

Indications	Allogeneic HCT	Autologous HCT
<i>Pediatric</i>		
Chronic phase	C	N
Accelerated phase	C	N
Blast phase	C	N
<i>Adult</i>		
Chronic phase, tyrosine kinase inhibitor intolerant	C	N
Chronic phase, tyrosine kinase inhibitor refractory	C	N
Chronic phase 2+	S	N
Accelerated phase	S	N
Blast phase	S	N

HCT: hematopoietic cell transplantation; CML: chronic myeloid leukemia; C: standard of care, clinical evidence available; N: not generally recommended; S: standard of care.

National Comprehensive Cancer Network (NCCN)

National Comprehensive Cancer Network CML guidelines (v.1.2026) recommend allo-HCT as an alternative treatment only for high-risk settings or in patients with advanced phase CML. (30) Relevant recommendations are:

- “Allogeneic HCT is an appropriate treatment option for patients with CP [chronic phase]-CML that is resistant and/or intolerant to all available TKIs [tyrosine kinase inhibitors], patients with disease progression to AP [accelerated phase]-CML during TKI therapy or patients with BP [blast phase]-CML who achieve morphologic remission.”
- “...Evaluation for allogeneic HCT is recommended for all patients with AP-CML or BP-CML”

Autologous HCT for CML is not addressed in the NCCN guidelines.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this policy are listed in Table 2.

Table 2. Summary of Key Trials

NCT Number	Trial Name	Planned Enrollment	Completion Date
------------	------------	--------------------	-----------------

NCT03314974	Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases	300	Jun 2027
NCT01760655	A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies	62	Dec 2022

NCT: national clinical trial.

Coding

Procedure codes on Medical Policy documents are included **only** as a general reference tool for each policy. **They may not be all-inclusive.**

The presence or absence of procedure, service, supply, or device codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. **Only the written coverage position in a Medical Policy should be used for such determinations.**

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member's benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT Codes	36511, 38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38220, 38221, 38222, 38230, 38232, 38240, 38241, 38242, 38243, 81265, 81266, 81267, 81268, 81370, 81371, 81372, 81373, 81374, 81375, 81376, 81377, 81378, 81379, 81380, 81381, 81382, 81383, 86805, 86806, 86807, 86808, 86812, 86813, 86816, 86817, 86821, 86825, 86826, 86828, 86829, 86830, 86831, 86832, 86833, 86834, 86835, 86849, 86950, 86985, 88240, 88241
HCPCS Codes	S2140, S2142, S2150

*Current Procedural Terminology (CPT®) ©2025 American Medical Association: Chicago, IL.

References

1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. May 2014; 89(5):547-556. PMID 24729196
2. Pavlu J, Szydlo RM, Goldman JM, et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. Jan 20 2011; 117(3):755-763. PMID 20966165
3. Gratwohl A, Pfirrmann M, Zander A, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. Mar 2016; 30(3):562-569. PMID 26464170
4. Fernandez HF, Kharfan-Dabaja MA. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. Cancer Control. Apr 2009; 16(2):153-157. PMID 19337201

5. Apperley JF. Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. *Hematology Am Soc Hematol Educ Program*. 2006;226-232. PMID 17124065
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med*. Dec 7 2006; 355(23):2408-2417. PMID 17151364
7. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*. Jun 17 2010; 362(24):2260-2270. PMID 20525995
8. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med*. Jun 17 2010; 362(24):2251-2259. PMID 20525993
9. Liu YC, Hsiao HH, Chang CS, et al. Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: prognosis revisited. *Anticancer Res*. Oct 2013; 33(10):4663-4667. PMID 24123046
10. Xu L, Zhu H, Hu J, et al. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. *Front Med*. Sep 2015; 9(3):304-311. PMID 26100855
11. Zhang GF, Zhou M, Bao XB, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia. *Asian Pac J Cancer Prev*. Nov 2016; 17(9):4477-4481. PMID 27797264
12. Shen K, Liu Q, Sun J, et al. Prior exposure to imatinib does not impact outcome of allogeneic hematopoietic transplantation for chronic myeloid leukemia patients: a single-center experience in china. *Int J Clin Exp Med*. 2015; 8(2):2495-2505. PMID 25932195
13. Chamseddine AN, Willekens C, De Botton S, et al. Retrospective study of allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive leukemia: 25 years' experience at Gustave Roussy Cancer Campus. *Clin Lymphoma Myeloma Leuk*. Jun 2015; 15 Suppl:S129-S140. PMID 26297265
14. Nair AP, Barnett MJ, Broady RC, et al. Allogeneic hematopoietic stem cell transplantation is an effective salvage therapy for patients with chronic myeloid leukemia presenting with advanced disease or failing treatment with tyrosine kinase inhibitors. *Biol Blood Marrow Transplant*. Aug 2015; 21(8):1437-1444. PMID 25865648
15. Piekarska A, Gil L, Prejzner W, et al. Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. *Ann Hematol*. Nov 2015; 94(11):1891-1897. PMID 26220759
16. Zhao Y, Luo Y, Shi J, et al. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia. *Am J Med Sci*. Jun 2014; 347(6):439-445. PMID 24553398
17. Egan DN, Beppu L, Radich JP. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations prior to allogeneic transplantation predominantly relapse with the same mutation. *Biol Blood Marrow Transplant*. Jan 2015; 21(1):184-189. PMID 25300870
18. Chakrabarti S, Buyck HC. Reduced-intensity transplantation in the treatment of hematological malignancies: current status and future prospects. *Curr Stem Cell Res Ther*. May 2007; 2(2):163-188. PMID 18220901

19. Crawley C, Szydlo R, Lanancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. *Blood*. Nov 1 2005; 106(9):2969-2976. PMID 15998838
20. Szatrowski TP. Progenitor cell transplantation for chronic myelogenous leukemia. *Semin Oncol*. Feb 1999; 26(1):62-66. PMID 10073562
21. Bhatia R, Verfaillie CM, Miller JS, et al. Autologous transplantation therapy for chronic myelogenous leukemia. *Blood*. Apr 15 1997; 89(8):2623-2634. PMID 9108379
22. McGlave PB, De Fabritiis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous leukemia: results from eight transplant groups. *Lancet*. Jun 11 1994; 343(8911):1486-1488. PMID 7911185
23. Podestà M, Piaggio G, Sessarego M, et al. Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis. *Exp Hematol*. Feb 2000; 28(2):210-215. PMID 10706077
24. Meloni G, Capria S, Vignetti M, et al. Ten-year follow-up of a single center prospective trial of unmanipulated peripheral blood stem cell autograft and interferon-alpha in early phase chronic myeloid leukemia. *Haematologica*. Jun 2001; 86(6):596-601. PMID 11418368
25. Boiron JM, Cahn JY, Meloni G, et al. Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias. *Bone Marrow Transplant*. Aug 1999; 24(3):259-264. PMID 10455363
26. McBride NC, Cavenagh JD, Newland AC, et al. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon. *Bone Marrow Transplant*. Dec 2000; 26(11):1165-1172. PMID 11149726
27. Michallet M, Thiebaut A, Philip I, et al. Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha. *Leukemia*. Dec 2000; 14(12):2064-2069. PMID 11187894
28. Pigneux A, Faberes C, Boiron JM, et al. Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience. *Bone Marrow Transplant*. Aug 1999; 24(3):265-270. PMID 10455364
29. Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. Jul 2020; 26(7):1247-1256. PMID 32165328
30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 1.2026. Available at <<https://www.nccn.org>> (accessed April 7, 2026).

Centers for Medicare and Medicaid Services (CMS)

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been changed since this medical policy document was written. See Medicare's National Coverage at <<https://www.cms.hhs.gov>>.

Policy History/Revision	
Date	Description of Change
06/15/2026	Document updated. Coverage unchanged. Updated reference 30; no new references added.
07/15/2025	Document updated with literature review. Coverage unchanged. Updated reference 30; no new references added.
08/15/2024	Reviewed. No changes.
02/01/2024	Document updated with literature review. Coverage unchanged. Updated reference 29.
05/15/2022	Reviewed. No changes.
12/01/2021	Document updated with literature review. Coverage unchanged. Added/updated the following references: 29-31.
01/15/2021	Document updated with literature review. Coverage unchanged. Updated reference 29; no new references added. Title changed from: Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous Leukemia (CML).
05/01/2019	Reviewed. No changes.
07/15/2018	Document updated with literature review. Coverage unchanged. References 12 and 31 added. Several references removed.
06/01/2017	Reviewed. No changes.
07/15/2016	Document updated with literature review. Coverage unchanged.
07/15/2015	Document updated with literature review. Coverage unchanged. Title changed from Stem-Cell Transplant for Chronic Myelogenous Leukemia (CML).
06/01/2014	Document updated with literature review. The following was changed: 1) Expanded coverage as follows donor leukocyte infusion (DLI) and hematopoietic progenitor cell (HPC) boost may be considered medically necessary for chronic myelogenous leukemia that has relapsed, to prevent relapse in the setting of a high-risk relapse, or to convert a patient from mixed to full chimerism; 2) DLI and HPC boost are considered experimental, investigational and/or unproven following an allogeneic stem-cell support (AlloSCS) treatment for CML that was originally considered experimental, investigational and/or unproven for the treatment of CML OR as a treatment prior to AlloSCS; 3) Short tandem repeat (STR) markers may be medically necessary when used in pre- or post-stem-cell support testing of the donor and recipient DNA profiles as a way to assess the status of donor cell engraftment following AlloSCS for CML; and 4) All other uses of STR markers

	are considered experimental, investigational and/or unproven if not listed in the coverage section.
04/01/2010	New medical document originating from: SUR703.017, Peripheral/Bone Marrow Stem Cell Transplantation (PSCT/BMT) for Non-Malignancies; SUR703.018, Peripheral/Bone Marrow Stem Cell Transplantation (PSCT/BMT) for Malignancies; SUR703.022, Cord Blood as a Source of Stem Cells (CBSC); SUR703.023, Donor Leukocyte Infusion (DLI); and SUR703.024, Tandem/Triple High-Dose Chemoradiotherapy with Stem Cell Support for Malignancies. Stem cell transplant continues to be medically necessary when stated criteria are met. NOTE: A link to the medical policies with the following titles can be found at the end of the medical policy SUR703.002, Stem-Cell Reinfusion or Transplantation Following Chemotherapy (General Donor and Recipient Information): • Peripheral/Bone Marrow Stem Cell Transplantation (PSCT/BMT) for Non-Malignancies; • Peripheral/Bone Marrow Stem Cell Transplantation (PSCT/BMT) for Malignancies; • Cord Blood as a Source of Stem Cells; • Donor Leukocyte Infusion (DLI); and Tandem/Triple High-Dose Chemoradiotherapy with Stem Cell Support for Malignancies.